Human Psychopharmacology: Clinical and Experimental 2005-10-01

Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome.

Jean-Daniel Favre, Hervé Allain, Henri-Jean Aubin, Elisabeth Frija-Orvoen, Claudine Gillet, Michel Lejoyeux, Alain Payen, Michel Weber, Stéphanie Garcia-Acosta, Imane Kermadi, Michel Dib

Index: Hum. Psychopharmacol. Clin. Exp. 20(7) , 511-9, (2005)

Full Text: HTML

Abstract

Cyamemazine is an original phenothiazine derivative which showed similar efficacy and tolerability to lorazepam during ethanol withdrawal in mice. This study investigated cyamemazine for its efficacy and tolerability in alcohol-dependent patients electing an alcohol withdrawal procedure, in comparison with diazepam.A multicenter, randomized, double-blind study in 89 alcohol-dependent patients (CIWA-Ar score between 10 and 30), electing an alcohol withdrawal procedure, was used to find effective doses of cyamemazine and to compare it with diazepam for efficacy and tolerability. On day 1 (D(1)), cyamemazine or diazepam (50 mg and 10 mg capsule, respectively) were administered at hourly intervals to reduce CIWA-Ar = 5, up to a maximum of eight administrations. Starting from D(2), the compounds were given twice a day in progressively decreasing doses during a maximum period of 13 days (D(end)).At h(8) (8 h after the first treatment of D(1)), therapeutic success (CIWA-Ar score